Harvard University

Kleinfeld Kaplan & Becker LLP Announces Election of Samantha N. Hong as Partner

Retrieved on: 
Wednesday, December 13, 2023
Legal, Professional Services, Harvard University, National Vaccine Program Office, Associate, Medicaid, Heated tobacco product, General counsel, Food, LLP, Justice, KKB, Cannabis, Tobacco, Research, Ground substance, FDA, Advertising, Meat, Cosmetics, Human services, Dietary supplement, HHS, Partnership, Harvard Law School, Public health, Medicare, Health, Poultry, Patent, Pharmaceutical industry

Kleinfeld Kaplan & Becker LLP (KKB) is pleased to announce that Samantha N. Hong has been elected to the partnership effective January 1, 2024.

Key Points: 
  • Kleinfeld Kaplan & Becker LLP (KKB) is pleased to announce that Samantha N. Hong has been elected to the partnership effective January 1, 2024.
  • Prior to her government service, Ms. Hong practiced patent litigation at large international law firms.
  • “Her promotion will strengthen our firm’s position among the most comprehensive FDA regulatory and advertising practices in the country.”
    Ms. Hong earned her J.D.
  • Kleinfeld Kaplan & Becker LLP is a Washington DC boutique law firm that has focused on food-and-drug and advertising law issues for over 60 years.

MassNAELA Honors State Representative Kate Hogan and Other Civic Leaders at Annual Meeting

Retrieved on: 
Wednesday, December 13, 2023
Professional Services, People with Disabilities, Consumer, Courts, State, Local, Healthcare Reform, Public Policy, Other Policy Issues, Legal, Seniors, Consulting, Government, Harvard University, Massachusetts Bar Association, National academy, Long-term care, Deborah, COVID-19, Undue hardship, IRS, Statehouse, Verrill, State government, Massachusetts Department of Correction, Superior court, Nursing, Boston

Massachusetts State Representative Kate Hogan was named the Legislator of the Year for her support of MassNAELA and her advocacy of the Undue Hardship, Pooled Trust, and Long-Term Care Reform bills.

Key Points: 
  • Massachusetts State Representative Kate Hogan was named the Legislator of the Year for her support of MassNAELA and her advocacy of the Undue Hardship, Pooled Trust, and Long-Term Care Reform bills.
  • Mattson partnered with MassNAELA to draft a letter to the Massachusetts Department of Revenue, engaging the Massachusetts Bar Association to participate as well.
  • MassNAELA member, Mary Paier Powers, Springfield, MA, was presented the Deborah H. Thomson Advocacy Award, which recognizes a MassNAELA member’s efforts in advocating for elder issues in state government.
  • The MassNAELA annual meeting also included the election of chapter officers and directors for the New Year.

Sofinnova Partners Launches Biovelocita, the First Pan-European Investment Strategy Dedicated to the Creation and Acceleration of Biotech Startups

Retrieved on: 
Wednesday, December 13, 2023
Professional Services, Health, Start-Up, Other Science, Finance, Science, Biotechnology, EOS, Harvard University, Acquisition, Luisa Seghezzi, Therapy, Acceleration, Lineage Cell Therapeutics, Ewing Marion Kauffman Foundation, Systems biology, Sofinnova, Partner, Growth, Doctor of Philosophy, Clovis Oncology, Pharmaceutical industry, Management

Sofinnova Partners (“Sofinnova"), a leading European life sciences venture capital firm based in Paris, London, and Milan, announced today the launch of Biovelocita , an investment strategy dedicated entirely to the creation and acceleration of biotech startups in Europe.

Key Points: 
  • Sofinnova Partners (“Sofinnova"), a leading European life sciences venture capital firm based in Paris, London, and Milan, announced today the launch of Biovelocita , an investment strategy dedicated entirely to the creation and acceleration of biotech startups in Europe.
  • The strategy builds upon Sofinnova’s established track record of nurturing innovative ventures within the healthcare and sustainability sectors.
  • Graziano Seghezzi, Managing Partner of Sofinnova Partners, said: “With Sofinnova Biovelocita, we are doubling down on our commitment to innovation and company creation in the life sciences.
  • Zhizhong (Joel) Yao , Partner, a former Principal in the Sofinnova Capital Strategy, and a Kauffman Fellow, instrumental in the launch of several biotech start-ups.

ImmunoScape Appoints Systems Immunology and Computational Biology Expert Dr. John Tsang to its Scientific Advisory Board

Retrieved on: 
Tuesday, December 12, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, General Health, Health, Biophysics, NIAID, TCR, Organization, Allen Institute, Executive Committee, National Cancer Institute, Cell Reports, University, Chan Zuckerberg Initiative, Master of Mathematics, Multimedia, Computational biology, Systems biology, Biomedicine, Allele, SAB, Machine learning, HLA, COVID-19, Kidney, Therapy, Intramural sports, NIH, World Allergy Organization, Cancer, Bangladesh Technical Education Board, CHI, Harvard University, Biomedical engineering, System, Digestive, Bachelor of Applied Science, Infection, Medical device, Management, Yale University, Columbia

ImmunoScape , a biotechnology company focused on next-generation immunotherapies, today announced the appointment of John Tsang, Ph.D. to its Scientific Advisory Board (SAB).

Key Points: 
  • ImmunoScape , a biotechnology company focused on next-generation immunotherapies, today announced the appointment of John Tsang, Ph.D. to its Scientific Advisory Board (SAB).
  • Dr. Tsang joins a distinguished group of leading scientists in immunology and oncology who help to guide ImmunoScape’s scientific strategy.
  • Dr. Tsang was also the Co-Director of the Trans-NIH Center for Human Immunology (CHI) and led its research program in systems human immunology.
  • Dr. Tsang has won multiple awards for his research, including several NIH/NIAID Merit Awards recognizing his scientific leadership in systems immunology, COVID-19, and human immunology research.

BioCT Names Dr. Stephen Bloch its 2023 Entrepreneur of the Year

Retrieved on: 
Tuesday, December 12, 2023
Oncology, Health, General Health, Research, Science, Biotechnology, Therapy, Shipman, Dartmouth College, Internal medicine, AB, Patient, Ebook, Partner, Ecosystem, Public policy, Committee, Radiology, University, MD, Growth, Lenox Hill, Selection Committee, Harvard University, Amusement park, Alexion

BioCT, the life sciences trade association for Connecticut, is thrilled to name Stephen Bloch, MD, the 2023 BioCT Entrepreneur of the Year, an award recognizing individuals who are imaginative, passionate, and game-changers in Connecticut bioscience.

Key Points: 
  • BioCT, the life sciences trade association for Connecticut, is thrilled to name Stephen Bloch, MD, the 2023 BioCT Entrepreneur of the Year, an award recognizing individuals who are imaginative, passionate, and game-changers in Connecticut bioscience.
  • A serial entrepreneur, Dr. Bloch is Co-founder and CEO/ Chairman of two CT-based companies, EvolveImmune Therapeutics and Allyx Therapeutics .
  • Dr. Bloch was honored at the BioCT’s 10th Annual Signature Holiday Event, held December 11, at Alexion in New Haven.
  • For more information about Dr. Bloch and past winners throughout the last 10 years, please see our 10th Anniversary E-Book .

Mission Bio Announces Over 20 Presentations Demonstrating the Utility of Tapestri Across AML, Multiple Myeloma, and Lymphoma at the 2023 ASH Annual Meeting

Retrieved on: 
Thursday, December 7, 2023
Science, Other Science, Research, Oncology, General Health, Health, Genetics, Clinical Trials, Harvard University, Multiple myeloma, Bone marrow, Identification, Landscape, DNA, MIT, ASH, Clonal hematopoiesis, University of Navarra, MFC, Patient, PCR, Mission, Cell, Medicine, Differentiation, MD Anderson Cancer Center, B cell, MRD, Merck, Blood, CNV, Flow cytometry, Exposition, MD, Survival, AML, Doctor of Philosophy, Society, Translational medicine, Genetic heterogeneity, Hospital, Genentech, Pharmaceutical industry, Vaccine, Hematology, Franses Tapestry Archive

The widespread adoption of Tapestri for hematological research and therapeutic development signifies the importance of single-cell multi-omic data and indicates a potential new gold standard in precision medicine.

Key Points: 
  • The widespread adoption of Tapestri for hematological research and therapeutic development signifies the importance of single-cell multi-omic data and indicates a potential new gold standard in precision medicine.
  • Detected MRD-positive patients, which were deemed negative by MFC and PCR,
    Differentiated between clonal hematopoiesis (CH) clones and leukemic clones.
  • Data from other blood cancer studies will be presented by leading researchers in over 24 presentations leveraging Mission Bio’s Tapestri Platform, showcasing its broad application in hematology.
  • For a complete list of ASH presentations using Tapestri, please visit our website .

CenCal Health Commemorates 40 Years of Quality Care in Santa Barbara County, 15 Years in SLO County

Retrieved on: 
Thursday, December 7, 2023
Insurance, Hospitals, Professional Services, Public Policy, Government, Health Insurance, Practice Management, Managed Care, State, Local, General Health, Health, Dignity, Harvard University, Editorial, Medicaid, Organization, Ford Foundation, Hospital, Pediatrics, Santa Barbara News-Press controversy, Multimedia, Patient, Medi-Cal, Partnership, Ford, Physician, Central Coast

The three physicians were each presented with a CenCal Health Partner Award in recognition of their exceptional service as primary care providers for CenCal Health, the Medi-Cal health plan for both Santa Barbara and San Luis Obispo counties.

Key Points: 
  • The three physicians were each presented with a CenCal Health Partner Award in recognition of their exceptional service as primary care providers for CenCal Health, the Medi-Cal health plan for both Santa Barbara and San Luis Obispo counties.
  • “CenCal Health is grateful for the partnership of local healthcare providers and county agencies,” said CenCal Health CEO Marina Owen.
  • The program – originally called the Santa Barbara Health Initiative – became known as CenCal Health, the nation’s first locally-administered Medicaid program of its kind.
  • The Santa Barbara Health Initiative, fulfilling the vision of Santa Barbara County's Health Care Services Director Dr. Lawrence Hart, brought local oversight to the Medi-Cal delivery system.

PlumCare and Fabric Genomics Announce a Strategic Partnership to Integrate the Fabric AI Platform with PlumCare’s FirstSteps™ Newborn Genome Screening Program in Greece

Retrieved on: 
Thursday, December 7, 2023
Data Management, Biotechnology, Baby, Maternity, Technology, Health, Health Technology, Software, Family, Artificial Intelligence, Genetics, Consumer, Harvard University, Genetic distance, RWE, WGS, Broad Institute, Entrepreneurship, MIT, Whole genome sequencing, Academy of Athens, Multimedia, Patient, Medicine, Textile, Ecosystem, Genomics, Science, Genome, Coronavirus Scientific Advisory Board, MD, Drug discovery, Partnership, Doctor of Philosophy, DSM-IV codes, Antibiotics, Medical device

PlumCare RWE and Fabric Genomics have partnered to deliver the Fabric AI platform with the PlumCare RWE FirstSteps newborn genome screening program in Greece.

Key Points: 
  • PlumCare RWE and Fabric Genomics have partnered to deliver the Fabric AI platform with the PlumCare RWE FirstSteps newborn genome screening program in Greece.
  • The goal of FirstSteps , a population health initiative, is to be able to screen every newborn in Greece by whole genome sequencing within the next five years.
  • View the full release here: https://www.businesswire.com/news/home/20231207013080/en/
    The FirstSteps program will leverage the power of the Fabric AI platform to offer rapid, accurate clinical genomic variant interpretation for whole genome sequencing (WGS) of screened newborns in Greece.
  • Fabric Genomics is proud to support the innovative PlumCare team to improve screening for babies in Greece by customizing its universal platform to the specific needs required in the national FirstSteps program.

Obatala Sciences Announces Commercial Launch of Its ObaCell® Obesity-on-a-Chip Service

Retrieved on: 
Tuesday, November 28, 2023
Research, Diabetes, Stem Cells, Biotechnology, Health, University, Pharmaceutical, Science, Education, Harvard University, B cell, Business development, Fasting, Food, MPS, Applied science, Applied physics, Biological engineering, Patient, Multimedia, DSM-IV codes, Doctor of Philosophy, Obesity, Physics, Investigational New Drug, Lipid, Therapy, MBA, Adipocyte, Family, Business, Food and Drug Administration, Physiology, Biology, Drug development, Adipose tissue, Pharmaceutical industry, Ọbatala, Engineering

Obatala Sciences, a biotechnology company that manufactures stem cells and human-derived hydrogels, announced the accomplishment of a major milestone with the commercial launch of its ObaCell® Obesity-on-a-Chip Service.

Key Points: 
  • Obatala Sciences, a biotechnology company that manufactures stem cells and human-derived hydrogels, announced the accomplishment of a major milestone with the commercial launch of its ObaCell® Obesity-on-a-Chip Service.
  • The new service reflects the commercial development of a family of patents that Obatala licensed from Harvard University in 2021.
  • Obatala Sciences is the first to market a technology that enables a more holistic understanding of human adipose tissue, which is an essential organ that impacts a wide array of metabolic diseases, including obesity and diabetes.
  • Obatala Sciences’ new service offering can reproduce the physiology of obese patients in a lab in ways never possible before, by overcoming size limitations for culturing mature adipocytes in a dish and simulating fasting and feeding in a human model system.

SolasCure Demonstrates Proof-of-Concept in Phase lla Safety Trial of Aurase Wound Gel

Retrieved on: 
Tuesday, December 12, 2023
Science, Biotechnology, Research, Pharmaceutical, Surgery, Health, Medical Devices, Clinical Trials, Harvard University, Safety, Simon Business School, University of Zurich, Senior, Erythema, INN, EIC, Patient, University of Rochester, Regenerative medicine, Medical Affairs Bureau, Wound healing, MBA, Bleeding, University, Phase, Debridement, Growth, Medicine, Doctor of Philosophy, Edema, Hydrogel, Pharmaceutical industry, Nursing, Boston, Dermatology

The CLEANVLU trial evaluated the Company’s first investigational product, Aurase Wound Gel, for use in chronic venous leg ulcer patients over 12 applications of the product (dosed every 3 days).

Key Points: 
  • The CLEANVLU trial evaluated the Company’s first investigational product, Aurase Wound Gel, for use in chronic venous leg ulcer patients over 12 applications of the product (dosed every 3 days).
  • SolasCure’s CLEANVLU Phase IIa clinical trial observed a strong safety profile for Aurase Wound Gel, with no evidence of systemic availability, no antibody generation to the enzyme and no effects on systemic coagulation pathways.
  • SolasCure’s Aurase Wound Gel, a hydrogel containing an enzyme cloned from medical maggots, aims to facilitate debridement, reduce bacterial biofilm, and promote wound bed preparation and healing.
  • Aurase Wound Gel is due to enter further Phase II trials to further evaluate its efficacy across a larger and more diverse patient group than the Phase IIa study, with the positive safety data obtained from the Phase IIa trial allowing for higher concentrations of the gel to now be explored.